Press Releases

Press Releases

March 18, 2014

Avedro Announces Receipt of Complete Response Letter from FDA for Corneal Cross‐Linking NDA

February 21, 2014

Avedro to Present at Cowen and Company 34th Annual Health Care Conference

November 25, 2013

Avedro Announces FDA Priority Review Status for Corneal Cross‐linking New Drug Application
If Approved, Avedro Could Be Entitled to Seven Years Market Exclusivity

November 14, 2013

Avedro and the University of Rostock (Germany) Announce Exclusive Intellectual Property Agreement
Avedro will Commercialize Patented Corneal Biomechanical Diagnostic

November 12, 2013

Avedro Announces the Start of Two New US FDA Trials for Accelerated Cross‐linking
Lasik with Cross‐linking and Pulsed Accelerated Cross‐linking

November 5, 2013

Avedro Announces CE Mark Clearance for its KXL II ™ Advanced Cross‐linking System
Offering the Potential for a Non‐surgical Alternative to Lasik and for Improving Cataract Surgery Outcomes

March 13, 2013

Avedro Announces Preparation for Anticipated Hyperopic Lasik Xtra® US Clinical Trial

March 5, 2013

Avedro Completes $43 Million Series D Financing
Abingworth and Third Point Join Existing Investors

October 25, 2012

Avedro and EyeGate Pharma Enter Agreement for Corneal Cross-linking IP
Avedro to hold exclusive license to broad iontophoresis patent portfolio

October 11, 2012

Keraflex® Keratoconus Treatment Study Begins in US
Hersh Vision Group is the first to offer this novel keratoconus treatment

June 12, 2012

Avedro Announces CE Mark for its Newest Riboflavin Formulations
The First Complete Family of Cross-linking Products

May 2, 2012

Avedro to Present Seven Scientific Research Posters at Leading Ophthalmic Meeting

April 3, 2012

ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking

March 8, 2012

Avedro Announces FDA Submission for Corneal Cross-linking

February 28, 2012

Avedro Options Rights to Intellectual Property
Avedro Options Rights to Intellectual Property

January 30, 2012

Canadian Approval for Lasik Xtra_Press Release

January 4, 2012

Avedro Announces CE Approval for Lasik Xtra ™
Intra-operative Lasik Cross-linking Receives Important European Recognition

December 6, 2011

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking
VibeX™ Riboflavin/KXL™ System for the Treatment of Corneal Ectasia Following Refractive Surgery

October 13, 2011

Avedro Appoints A. John Kanellopoulos, MD to its Medical Advisory Board
Dr. Kanellopoulos is globally recognized as a pioneer in refractive surgery and corneal cross-linking

September 28, 2011

Avedro Appoints C. Evan Ballantyne as Chief Financial Officer
The Company Prepares for Rapid Commercialization

September 14, 2011

Avedro Acquires Patent Portfolio for Breakthrough Transepithelial Riboflavin        
Inventor Roberto Pinelli, MD will join the Avedro Medical Advisory Board

September 12, 2011

Avedro Announces FDA Orphan Drug Designation for Its Corneal Cross-linking
VibeX™ Riboflavin/KXL™ System for the Treatment of Keratoconus

July 20, 2011

Avedro and Japan’s Shinagawa LASIK Centers Announce Their Expanded Commercial Relationship
The Shinagawa LASIK Center in Tokyo has performed more Lasik surgeries than any other center in the world

July 7, 2011

Avedro Completes $25 Million Series C Financing
SCP Vitalife and Aperture Venture Partners join existing investors

May 17, 2011

Avedro Announces Completion of 1st US Phase III Corneal Cross-linking Clinical Trials
Multi-center US Phase III Studies for the Treatment of Progressive Keratoconus and Ectasia Following Refractive Surgery

April 20, 2010

Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device
The company prepares for immediate commercial launch throughout Europe and Asia

March 16, 2010

Avedro Becomes Sponsor of US FDA Clinical Trials of Corneal Collagen Crosslinking
Deal opens a new and substantial business opportunity for Avedro’s Keraflex® KXL

December 16, 2009

Avedro Initiates Keraflex® KXL Clinical Trials for Treating Keratoconus
Initial results demonstrate significant corneal flattening, improved visual outcomes

The Vedera for performing the Keraflex procedure, and the KXL System for Accelerated Cross-linking are not available for sale in the United States.